Julie L. Tyler - Feb 17, 2023 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Role
SENIOR VICE PRESIDENT
Signature
/s/ Julie L. Tyler by Jessica H. Paik, Attorney-in-Fact
Stock symbol
ABT
Transactions as of
Feb 17, 2023
Transactions value $
-$94,302
Form type
4
Date filed
2/22/2023, 06:20 PM
Previous filing
Jul 27, 2022
Next filing
Mar 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABT Common shares without par value Award $0 +7.92K +23.38% $0.00 41.8K Feb 17, 2023 Direct F1
transaction ABT Common shares without par value Tax liability -$31.1K -291 -0.7% $106.74 41.5K Feb 19, 2023 Direct
transaction ABT Common shares without par value Tax liability -$36.4K -341 -0.82% $106.74 41.2K Feb 21, 2023 Direct
transaction ABT Common shares without par value Sale -$26.8K -260 -0.63% $103.24 40.9K Feb 22, 2023 Direct
holding ABT Common shares without par value 9.51K Feb 17, 2023 Profit Sharing Trust F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABT Option (right to buy) Award $0 +31.2K $0.00 31.2K Feb 17, 2023 Common Shares 31.2K $106.24 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
F2 Balance in the Abbott Laboratories Stock Retirement Trust as of February 17, 2023.
F3 Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 10,412 on February 17, 2024, 10,412 on February 17, 2025 and 10,412 on February 17, 2026.